PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2011-06-01 / J. Immunother. 2011 Jun;34(5):409-18Immunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-61Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
/in Dendritic Cells, International Publications /von 2011-05-12 / Cell. Immunol. 2011;270(2):188-97Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-67Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-107Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-05-01 / J. Immunother. 2011 May;34(4):382-9The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells
/in Dendritic Cells, International Publications /von 2011-04-25 / Clin Med Insights Oncol 2011;5:107-15Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer /von 2011-04-20 / PLoS ONE 2011 Apr;6(4):e18801Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF
/in Dendritic Cells, International Publications /von 2011-04-05 / Mol. Ther. 2011 Aug;19(8):1558-68
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de